Valneva (VALN) Stock: Buy, Sell, or Hold?

VALN - Valneva SE American Depositary Shares

Biological Products, (No Diagnostic Substances)
$5.74
-0.16 (-2.71%) ▼
5d: -6.51%
30d: -19.38%
90d: +6.3%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 19, 2026

Get Alerted When VALN Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
📊 MIXED SIGNALS: VALN shows conflicting indicators. Wait for confirmation before entering.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$9.50
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.90
2.7% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.7x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: VALN is currently trading at $5.74, which is considered oversold relative to its 30-day fair value range of $6.21 to $6.83. From a valuation perspective, the stock is trading at a discount (Forward PE: 4.8) compared to its historical average (5.7). Remarkably, the market is currently pricing in an annual earnings decline of 5.5% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, VALN is in a uptrend. The price is currently testing key support at $5.73. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.25 (+113.4%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position OVERSOLD
Historical Trading Range $6.21 - $6.83
Company Quality Score 44/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 79.5%

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 113.4% below Wall St target ($12.25)
  • WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $6.21 - $6.83
Current vs Trading Range OVERSOLD

Support & Resistance Levels

Support Level $5.73
Resistance Level $6.68
Current Trend Uptrend
Technical data as of Oct 2, 2026

Fundamental Context

Forward P/E (Next Year Est.) 4.82
Wall Street Target $12.25 (+113.4%)
Revenue Growth (YoY) -27.7%
Profit Margin -110.3%
Valuation Discount vs History -5.5% cheaper
PE vs Historical 4.8 vs 5.7 CHEAP
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -5.5% (market-implied from PE analysis)
1-Year Target $5.42 (-6%)
2-Year Target $5.13 (-11%)
3-Year Target $4.84 (-16%)
3-Yr Target (if PE normalizes) (PE: 5→6) $5.72 (0%)
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 4.8 to 5.7
Stabilization Target: $6.78 (+18.2%)
PE Expansion Potential: +18.2%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: October 03, 2026 7:29 AM ET
Data refreshes hourly during market hours. Next update: 8:29 AM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Technical Signals Check
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL

Unlock Insider Activity

See real-time buying/selling by company executives for VALN.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
BMRN
Biomarin Pharmaceutical …
STRONG BUY
29 analysts
$92 46 HOLD
BBIO
BridgeBio Pharma Inc
STRONG BUY
19 analysts
$109 76 BUY
NRIX
Nurix Therapeutics Inc
STRONG BUY
18 analysts
$34 65 BUY
AXSM
Axsome Therapeutics Inc
STRONG BUY
19 analysts
$285 42 HOLD
INCY
Incyte Corporation
HOLD
27 analysts
$128 56 HOLD

More Analysis for VALN

VALN Technical Chart VALN Price Prediction VALN Earnings Date VALN Investment Advisor VALN Fair Price Analyzer VALN Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals